Camurus (CAMX)

Executive Summary

Camurus is a Swedish biopharmaceutical company that has leveraged its proprietary FluidCrystal® drug delivery technology to develop a pipeline of long-acting injectable formulations for severe chronic diseases. Founded in 1991 and headquartered in Lund, the company focuses on improving patient outcomes through sustained-release medicines that reduce dosing frequency and enhance compliance. Camurus’s lead asset, CAM2029 (octreotide), targets acromegaly and neuroendocrine tumors, with a regulatory decision in the EU expected soon. Additionally, the company is advancing CAM2038 (buprenorphine) for chronic pain and CAM2048 (pasireotide) for Cushing's disease, alongside a partnered program in opioid use disorder. With a validated platform and multiple late-stage assets, Camurus is positioned to address significant unmet needs in endocrinology, pain management, and addiction medicine. The company’s commercial strategy includes direct marketing in key European markets and partnerships in the US and other regions. Buvintix® (buprenorphine) for opioid dependence is already approved in Europe, providing a revenue base. The upcoming EU decision on CAM2029 represents a near-term catalyst that could drive significant value, while phase 3 data for CAM2038 in chronic pain and potential platform out-licensing offer additional upside. Camurus’s focus on long-acting technologies aligns with healthcare trends toward patient-centric treatments, and its robust pipeline supports a positive outlook. With a strong balance sheet and experienced management, the company is well-equipped to execute its strategic plan.

Upcoming Catalysts (preview)

• Q4 2026EU approval decision for CAM2029 (octreotide) in acromegaly70% success
• H1 2027Phase 3 top-line data for CAM2038 (buprenorphine) in chronic pain60% success
• TBDPartnership or licensing deal for FluidCrystal® platform50% success